{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 32,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "appendix",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a Gantt-style timeline to show the duration of IP protection and exclusivity for various therapeutic assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/29",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.8,
        "x": 0.175,
        "y": 0.16
      },
      "kind": "chart",
      "text": "Timeline of patent and exclusivity coverage from 2006 to 2044",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce819f31-a393-4a5e-9eb6-132063b63589",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.16,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Assumptions: Listed applications will issue; Biologics Exclusivity will be granted and will begin at NDA approval; Potential patent term extensions not shown",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e626733-9f97-4a8f-8492-16e45592331a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.52,
        "y": 0.945
      },
      "kind": "disclaimer",
      "text": "Itolizumab filings under exclusive license to Equillium for US, CA, AU, NZ. Cytokine Technologies are wholly owned and under prosecution in all major global markets",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "889ad158-2651-4ffb-86ae-f8d844226f8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.03,
        "y": 0.81
      },
      "kind": "legend",
      "text": "Biocon Filings vs EQ Filings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5477235f-c5a4-4d5d-9886-abea94e4746d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Itolizumab: 11 patent families, 26 issued patents, 31 applications pending (as of August 2023)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22250529-b97c-40e7-b0da-db88d22b3ec0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "Multi-Cytokine Technologies: 6 patent families, 33 issued patents, 44 applications pending (as of August 2023)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50ab87e9-83dd-4869-a860-1b5497e51bce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Equillium Intellectual Property & Regulatory Exclusivity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7eec874-3f45-46ee-9caa-5b9183333a15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "9d041132-f306-4236-8dc0-7e2bd029316f",
      "evidence": "Timeline visualization of overlapping patent and exclusivity periods",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}